An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Precision BioSciences, Inc. (NASDAQ: DTIL) announced plans to release its financial results for Q4 and the fiscal year 2022 on March 9, 2023. The company is focused on gene editing through its proprietary ARCUS® platform, aiming to develop allogeneic CAR T and in vivo therapies to treat genetic and infectious diseases. With its innovative approach, Precision is committed to advancing treatments where no adequate solutions currently exist.
Positive
Company is advancing gene editing with proprietary ARCUS® platform.
Focus on developing 'off-the-shelf' CAR T immunotherapy and in vivo therapies.
Negative
None.
DURHAM, N.C.--(BUSINESS WIRE)--
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
